Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

NAPLEX 2024 > 44. Diabetes > Flashcards

44. Diabetes Flashcards

1
Q

Diabetes is due to decreased___ , ____, or both

A

insulin secretion, insulin sensitivity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define T1DM

A

Autoimmune destruction of beta-cells (no beta-cells = no insulin production)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define T2DM

A

insulin resistance and insulin deficiency due to beta-cell damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Metformin can be used in prediabetes pts with BMI ___, age ___, and women with hx of ____

A

BMI ≥35, age <60 yo, and women with hx of GDM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pregnant women are tested for GMD at ___ using ____

A

24-28 weeks using oral glucose tolerance test (OGTT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Risk factors of DM

A

Physical inactivity
Overweight (BMI ≥25 or 23 in asian-americans)
Race (AA, asian-american, latino/hisptanic-american, native american, pacific islander)
Hx of GDM
A1C ≥ 5.7%
First-degree relative with DM (sibling/parent)
HLD, HTN, CVD, smoking
Other conditions that cause insulin resistance (e.g. acanthosis, nigricans, PCOS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Symptoms of DM

A

Polyuria, polyphagia, polydipsia, fatigue, blurry vision, erectile dysfunction, vaginal fungal infections
T1DM - initial presentation is often DKA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Screening start age

A

35 yo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

All asymptomatic children, adolescents, and adults who are ____ and have at least 1 other risk factor should be tested and repeat every ____ years if normal

A

overweight (BMI ≥25 or 23 for asian-americans), repeat every 3 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

There are 3 types of DM tests: ___, ___, and ___. ___ is preferred.

A

Hg A1C, fasting plasma glucose (FPG), and OGTT. No single test is preferred.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

T/F: Positive DM test does not require another test to confirm

A

Positive test should be confirmed with a second abnormal test result unless clear clinical diagnosis (e.g classic symptoms + random BG ≥ 200)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Diagnosis Criteria for DM A1C

A

A1C ≥ 6.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Diagnosis Criteria for Pre-diabetes A1C

A

5.7-6.4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Diagnosis Criteria for DM FPG (mg/dL)

A

≥126

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diagnosis Criteria for Pre-diabetes FPG (mg/dL)

A

100-125

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Diagnosis Criteria for DM OGTT (2hr BG, mg/dL)

A

≥ 200

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Diagnosis Criteria for Pre-diabetes OGTT (2hr BG, mg/dL)

A

140-199

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Treatment goals for A1C for non-pregnant

A

<7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Treatment goals for Pre-prandial for non-pregnant

A

80-130

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Treatment goals for Pre-prandial for pregnant

A

≤95

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Treatment goals for 2hr PPG for non-pregnant

A

<180

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Treatment goals for 1hr PPG for pregnant

A

≤140

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Treatment goals for 2hr PPG for pregnant

A

≤120

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

A1C testing frequency if not at goal

A

every 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

A1C testing frequency if at goal

A

every 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

A1C to estimated average glucose (eAG) math

A

A1C 6% = 126 mg/dL + additional 1% = 28 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Waist circumference goal for females

A

<35 inches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Waist circumference goal for females

A

<40 inches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

1 serving = ___ grams of carbs (list examples)

A

15 g of carbs = 1 small piece of fruit, 1 slice of bread, OR ⅓ cup of cooked rice/pasta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Physical Activity recommendation

A

At least 150 min/week of moderate intensity activity
Reduce sedentary habits, stand every 30 min at minimum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Micro or macrovascular disease: Retinopathy

A

Microvascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Micro or macrovascular disease: Diabetic kidney disease (i.e. neuropathy)

A

Microvascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Micro or macrovascular disease: Peripheral neuropathy (i.e. loss of sensation, often in feet, increased risk of foot infections and amputations)

A

Microvascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Micro or macrovascular disease: Autonomic neuropathy (gastroparesis, loss of bladder control, erectile dysfunction)

A

Microvascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Micro or macrovascular disease: Coronary artery disease (CAD), including MI

A

Macrovascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Micro or macrovascular disease: Cerebrovascular disease (CVA), including stroke

A

Macrovascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Micro or macrovascular disease: Peripheral artery disease (PAD)

A

Macrovascular

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

T/F: ASA 81mg is recommended for primary prevention in all patients

A

False - ASA 81mg daily is recommended for ASCVD secondary prevention (e.g. post-MI)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Alternative for secondary ASCVD prevention in DM patients if aspirin allergy

A

clopidogrel 75mg daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

High or moderate intensity statin: DM patient with ASCVD

A

High intensity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

High or moderate intensity statin: DM patient age 40-75yo with ≥ 1 ASCVD risk factor

A

High intensity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

High or moderate intensity statin: DM patient age 40-75yo (no ASCVD)

A

Moderate intensity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

High or moderate intensity statin: DM patient age <40 yo with ASCVD risk factors

A

Moderate intensity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Icosapent ethyl (Vascepa) can be added on for cholesterol control if LDL ___ and TG ____

A

LDL is controlled but TG is 135-299 mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

DM patient lipid panel monitoring frequency

A

Annually, 4-12 weeks after starting statin or increasing dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

DM patient eye exam monitoring frequency

A

eye exam at dx, annually if retinopathy, can defer to every 1-2 years otherwise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Required vaccinations for DM patients (in addition to all childhood vaccines)

A

Hep B, influenza (annually), pneumococcal vaccines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Diabetic kidney disease definition

A

eGFR < 60 and/or albuminuria (urine albumin ≥ 30mg/24hrs or UACR≥30 mg/g)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Treatment options for diabetic kidney disease

A

ACEi/ARB, SGLT2i (if eGFR ≥20) or finerenone (once on max tolerated dose of ACEi/ARB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

DM neuropathy monitoring frequency

A

Sensation - annually with 10g monofilament test and 1 other test (pinprick, temp, vibration)
Comprehensive foot exam - at least annually

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

DM Foot care counseling points

A

Daily: wash, dry, and examine feet, moisturize top and bottom of feet but NOT between toes
Each office visit: check feet
Annually: foot exam by podiatrist
Trim toenails with nail file
Wear socks and shoes, elevate feet when sitting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

BP goal for DM patient

A

<130/80

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

BP treatment options for DM with no albuminuria or CAD

A

thiazide, DHP CCB, ACEi/ARB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

BP treatment options for DM with albuminuria or CAD

A

ACEi/ARB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Natural products used for DM

A

cinnamon, alpha lipoic acid, chromium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

LDL goal for DM patients

A

LDL <55 if ASCVD, <70 for all others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

Insulin can be used initially in T2DM patients if ___ or ____

A

severe hyperglycemia: A1C > 10% or BG ≥ 300

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Recommended to start 2 drugs at baseline in T2DM patients if A1C ____

A

8.5-10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Start ___ or ___ if T2DM patients has ASCVD, HF, or CKD

A

GLP1RA or SGLT2i

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

T2DM medication combinations to avoid

A

DPP-4i + GLP1RA
SU + insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

GLP-1 RA MOA

A

Analogs of GLP-1 hormone which increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying/improves satiety (=weight loss)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

GLP1RA dose frequency:
Liraglutide (Victoza)
Dulaglutide (Trulicity)
Semaglutide (Ozempic)
Exenatide (Byetta)
Exenatide ER (Byetta BCise)

A

Liraglutide (Victoza) - SC daily
Dulaglutide (Trulicity) - SC once weekly
Semaglutide (Ozempic) - SC once weekly, PO once daily
Exenatide (Byetta) - SC BID
Exenatide ER (Byetta BCise) - SC once weekly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Dual GLP-1 and GIP agonist dose frequency: Tirzepatide (Mounjaro)

A

SC weekly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Which GLP1RAs are recommended in patients with ASCVD (or high risk) and as an alternative in CKD because of CV benefits?

A

Liraglutide (Victoza)
Dulaglutide (Trulicity)
SC semaglutide (Ozempic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Which GLP1RA also comes in an oral tablet formulation?

A

Semaglutide (Rybelsus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

GLP1 RA names end in “-___”

A

“-tide”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

GLP1 RA (except Byetta) Boxed warning

A

increased risk of thyroid C-cell carcinoma
Do NOT use if personal or family hx of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

GLP1 RA Warnings

A

Pancreatitis (can be fatal, RF: gallstones, alcoholism, or increased TGs)
NOT recommended in pts with severe GI disease, including gastroparesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Bydureon BCise warnings

A

Serious injection-site reactions (e.g. abscess, cellulitis, necrosis) with or w/o SC nodules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Ozempic and Mounjaro warnings

A

increased complications with diabetic retinopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Which GLP1RAs have increased complications with diabetic retinopathy

A

Ozempic and Mounjaro

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Side effects of GLP1RAs and GIP agonists

A

Weight loss, N/V/D (reduced with dose titration), hypoglycemia, injection site reactions, AKI, gallbladder disease
Tirzepatide: increased HR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

GLP1 RA and GIP agonist A1C decrease %

A

0.5-1.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

GLP1 RA and GIP agonist effect on BG

A

decreases postprandial BG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

GLP1 RA and GIP agonist hypoglycemic risk

A

Low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

Do NOT use GLP1 RA and GIP agonists with ___ (overlapping mechanism)

A

DPP-4 inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

Exenatide (Byetta) dose timing with meals

A

within 60min of meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

Semaglutide (Rybelsus) dose timing with meals

A

Take does ≥30 min before first food/drink/meds of the day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

Pen needles are not provided with ___ or ____ but provided with all other GLP1RAs

A

Byetta or Victoza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

T/F: Glucose-lowering effects are often seen immediately with initial doses of GLP1 RAs

A

False - often not seen with initial doses (titrated to reduce GI ADEs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

GLP1RAs can (increase/decrease) INR in patients on warfarin

A

Increase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

SGLT2 inhibitor MOA

A

Inhibits SGLT2 (expressed in proximal renal tubules, responsible for reabsorption of filtered glucose), reduces reabsorption of glucose and increases glucose in urine excretion (decrease BG)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

Which SGLT2is have shown benefits in patients with HF, CKD, and/or ASCVD?

A

Canagliflozin, dapagliflozin, and empagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

SGLT2i names end in “-____”

A

“-gliflozin”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

SGLT2i dosing frequency and timing

A

once daily in the morning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

SGLT2i contraindications

A

Dialysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

SGLT2i warnings

A

Ketoacidosis (can occur with BG <250, D/C prior to surgery d/t risk)
Genital mycotic infections, urosepsis, pyelonephritis, necrotizing fasciitis (perineum)
Hypotension, AKI, and renal impairment (d/t intravascular volume depletion)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

Canagliflozin (Invokana) warnings

A

Increase risk of leg and foot amputations, higher risk with hx of amputation, PAD, peripheral neuropathy and/or diabetic foot ulcers
Hyperkalemia risk when used with other drugs that increase potassium
Risk of fractures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

SGLT2i side effects

A

weight loss, increase urination, increase thirst, hypoglycemia, increase Mg/PO4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

SGLT2i A1C lowering %

A

0.7-1%

91
Q

SLGT2i hypoglycemia risk

A

low (unless used with insulin)

92
Q

SGLT2i have increased risk of intravascular volume depletion (causing ___ and ___) if used in combination with ____, ___, and ____

A

causing hypotension and AKI if used in combination with diuretics, RAAS inhibitors, or NSAIDs

93
Q

Uridine diphosphate glucuronosyltransferase (UGT) inducers (e.g. ___, __, ____) can (increase/decrease) canagliflozin levels

A

rifampin, phenytoin, phenobarbital can decrease canagliflozin levels
Consider using 300mg dose if used in combo and eGFR≥60

94
Q

Metformin MOA

A

decrease hepatic glucose production
increase insulin sensitivity
decrease intestinal absorption of glucose

95
Q

Metformin boxed warning

A

Lactic acidosis - increased risk with renal impairment, contrast dye, and excessive alcohol/drugs

96
Q

Metformin contraindications

A

eGFR <30, acute or chronic metabolic acidosis (includes DKA)

97
Q

Metformin warnings

A

NOT recommended to start if eGFR 30-45 (reassess if already taking and eGFR falls <45)
VitB12 deficiency: s/sx can include peripheral neuropathy and cognitive impairment; monitor B12 levels periodically (e.g. every 1-2 years)

98
Q

Metformin ADEs

A

GI effects (diarrhea, nausea, flatulence, cramping)
Typically transient

99
Q

Metformin A1C lowering %

A

1-2%

100
Q

Metformin weight effect

A

Neutral

101
Q

Metformin hypoglycemia risk

A

No hypoglycemia

102
Q

Metformin ER can leave ____ in stool

A

ghose tablet

103
Q

Intra-arterial ____ (used for imaging studies) can increase risk of lactic acidosis. Discontinue metformin before imaging procedure. Restart metformin ___ after procedure if eGFR is stable.

A

Iodinated contrast media, 48hrs

104
Q

Alcohol can ____ risk of lactic acidosis

A

increase
excessive intake, acute or chronic, should be avoided

105
Q

Which can increase risk of lactic acidosis with metformin?

A

Iodinated contrast media
alcohol
topiramate + metformin

106
Q

SUs and meglitinides MOA

A

stimulate insulin secretion from pancreatic beta-cells to decrease postprandial BG

107
Q

Meglitinides have (faster/slower) onset and (shorter/longer) duration of action compared to SUs

A

faster onset (15-60min) and shorter duration of action

108
Q

Name 3 older, first generation SUs (should NOT be used)

A

chlorpropamide, tolazamide, and tolbutamide

109
Q

Meglitinide names end in “-____”

A

“-glinide”

110
Q

SUs names start with “__” and end in “-___”

A

Start with G and end with “-ide”

111
Q

SUs contraindications

A

Sulfa allergy ( not likely to cross-react)

112
Q

SUs warnings

A

hypoglycemia

113
Q

SUs ADEs

A

Weight gain, nausea

114
Q

SUs A1C lowering %

A

1-2%

115
Q

T/F: Efficacy of SUs increase the longer you use it

A

False - decreased efficacy after long-term use (as pancreatic beta-cell function declines)

116
Q

Glipizide IR dose timing with meals

A

Take 30 min before meals
All other products taken with breakfast or first meal of the day
May need to hold doses if NPO

117
Q

Glucotorol XL is an OROS formulation and can leave a ___ in stool

A

ghost tablet

118
Q

Which SUs are not preferred in elderly (Beers criteria) d/t hypoglycemia risk

A

Glimepiride, glyburide

119
Q

Patients with ___ deficiency can be increased risk of hemolytic anemia with SUs

A

G6PD

120
Q

Repaglinide dose timing with meals

A

Take 15-30 min before meals

121
Q

Nateglinide dose timing with meals

A

1-30 min before meals

122
Q

Meglitinides contraindications

A

T1DM, DKA

123
Q

Meglitinides warnings

A

Hypoglycemia, caution with severe liver/renal impairment

124
Q

Meglitinides ADEs

A

weight gain, HA, URTIs

125
Q

Meglitinides A1C lowering %

A

0.5-1.5%

126
Q

SUs are CYP___ substrates, use caution with inducers or inhibitors

A

CYP2C9

127
Q

___ and ___ can increase repaglinide, leading to decrease BG

A

Gemfibrozil and clopidogrel

128
Q

Repaglinide is contraindicated with ___

A

Gemfibrozil

129
Q

___ can increase the risk for delayed hypoglycemia when taking insulin or insulin secretagogues (SUs or meglitinides)

A

Alcohol

130
Q

DPP-4i prevent enzyme DPP-4 from breaking down ____

A

incretin hormones, GLP1 and GIP

131
Q

DPP-4i MOA

A

prevent DPP-4 breakdown of GLP1 and GIP, increase insulin release from pancreatic beta-cells and decrease glucagon secretion (decreases hepatic glucose production) from pancreatic alpha-cells
Enhance the effects of the body’s own incretins

132
Q

DPP-4i names end in “-___”

A

“-gliptin”

133
Q

Which DPP-4is require renal dose adj

A

Sitagliptin (Januvia)
Saxagliptin (Onglyza)
Alogliptin (Nesina)

134
Q

Which DPP-4is do NOT require renal dose adj

A

Linagliptin (Tradjenta)

135
Q

DPP-4i warnings

A

Pancreatitis, severe arthralgia (joint pain), acute renal failure, hypersensitivity reactions, bullous pemphigoid (blisters/erosions requiring hospitalization)
Risk of HF wtih saxagliptin and alogliptin, but warning added for class
Alogliptin: hepatotoxicity

136
Q

Which DPP-4i has warning of hepatotoxicity?

A

Alogliptin (Nesina)

137
Q

DDP-4i ADEs

A

generally well tolerated, can cause nasopharyngitis, URTIs, UTIs, peripheral edema, rash

138
Q

DPP-4i A1C lowering %

A

0.5-0.8%

139
Q

DPP-4i weight effect

A

neutral

140
Q

DPP-4i hypoglycemia risk

A

Low

141
Q

DPP-4i and ___ have overlapping mechanisms and should be used together

A

GLP1RA

142
Q

Saxagliptin is a major substrate of CYP___ and ___. Limit the dose to ___ with strong inhibitors including protease inhibitors (e.g. ___,____) and anti-infectives (___,___,___)

A

CYP3A4 and P-gp
Limit dose to 2.5mg
atazanavir, ritonavir
Clarithromycin,itraconazole, ketoconazole

143
Q

Linagliptin is a major substrate of CYP___ and ___. Decreased linagliptin levels with strong inducers (e.g. ___, ___, ___, ___)

A

3A4 and pgp
Carbamazepine, phenytoin, rifampin, St. John’s wort

144
Q

Thiazolidinediones (TZDs) MOA

A

Perozisome proliferator-activated receptor gamma (PPAR𝛾) agonist that increase peripheral insulin sensitivity (increase uptake and utilization of glucose by peripheral tissues, aka insulin sensitizers)

145
Q

___ is currently the only TZD available in the US

A

Pioglitazone

146
Q

TZD boxed warning

A

Can cause or exacerbate HR, do NOT use with NYHA class III/IV HF

147
Q

TZD Warning

A

Edema (including macular edema), risk of fractures, hepatic failure, can stimulate ovulation (can lead to unintended pregnancy)
Increase risk of bladder cancer (do NOT use in pts with hx of bladder cancer)

148
Q

TZD ADEs

A

Peripheral edema, weight gain, URTIs, myalgia

149
Q

TZD A1C Lowering

A

0.5-1.4%

150
Q

TZD hypoglycemia risk

A

Low

151
Q

TZD is a major substrate of CYP___, use caution with inducers (e.g. ___) or inhibitors (e.g.___)

A

2C8
rifampin
gemfibrozil

152
Q

When using ___ and hypoglycemia occurs, it cannot be treated with sucrose (fruit juices, table sugar, or candy); glucose tablets/gel must be used to treat hypoglycemia

A

Alpha-glucosidase inhibitors - acarbose or miglitol (Glyset)

153
Q

Alpha-glucosidase inhibitors (acarbose, miglotiol (Glyset)) administration instructions

A

Each dose should be taken with first bite of each meal

154
Q

Pramlintide (Symlin) hypogylcemia risk

A

Significant hypoglycemia risk - must reduce mealtime insulin dose by 50% when starting

155
Q

Basal insulin examples

A

glargine
detemir
degludec

156
Q

Rapid-acting insulin examples

A

aspart
lispro
glulisine

157
Q

Short-acting insulin

A

regular insulin

158
Q

What insulin is contraindicated in any lunch disease, including asthma or COPD?

A

Inhaled insulin (Afrezza)

159
Q

General side effects of insulin

A

Weight gain
Lipoatrophy (loss of SC fat at injection site, disfigures skin)
Lipohypertrophy (accumulation of fat lumps under injection site)
Tip: Rotate injection sites and use analog insulins (lower risk than older insulins)

160
Q

Most insulin vials are ___mL and most insulin pens are ___mL

A

10mL
3mL

161
Q

Any percentage mixture of NPH and regular (or rapid-acting) can be made by mixing in a syringe. Which insulin should be drawn up first?

A

Draw up regular insulin (or rapid-acting, clear insulin) first
Then NPH (cloudy)

162
Q

____ is a ready to use (TRU) regular insulin IV bag

A

Myxredlin

163
Q

___ insulin is preferred for IV infusions, including parenteral nutrition; less expensive than other insulins and onset is immediate when administered as continuous IV (Note: should be prepared in non-PVC container)

A

Regular insulin

164
Q

When should regular insulin be administered?

A

SC 30 min before meals

165
Q

When should aspart or lispro insulin be administered?

A

SC 5-15 min before meals
Lispro can also be administered right after eating
Fiasp-aspart and Lyumjev-lispro can be injected with first bite or within 20 min of starting a meal

166
Q

Regular U-500 has many safety risks. In what situations can you use it?

A

When patients require > 200 units of insulin per day
Note: U-500 insulin syringes must be prescribed to avoid errors, do NOT mix with any other insulin

167
Q

GLP1RAs are typically preferred before starting insulin. When would you temporarily initiate insulin in T2DM patients?

A

If A1C >10% or BG ≥300

168
Q

Explain starting step-approach regimen for insulin in T2DM

A

Basal first - 10 units SC daily or 0.1-0.2 units /kg/day (titrate)
If not at goal, add prandial - 4 units or 10% basal dose once daily prior to largest meal (titrate)
If not at goal, full basal/bolus regimen or mixed insulin

169
Q

Explain starting basal-bolus insulin regimen for insulin in T1DM

A

Calculate TDD (0.5 units/kg/day, using TBW)
50% is bolus, 50% basal
Bolus split evenly into 3 meals
Note: if NPH and regular regimen (not preferred): split 2/3 NPH and 1/3 regular

170
Q

Which parts of the insulin pump need to be replaced regularly?

A

insulin reservoir, tubing, and infusion set

171
Q

___ insulin uses Rule of 450 and ___ insulin uses Rule of 500 for insulin-to-carbohydrate ratio (ICR)

A

Regular = rule of 450
Rapid-acting = rule of 500

172
Q

___ insulin uses Rule of 1500 and ___ insulin uses Rule of 1800 for correction factor

A

Regular = rule of 1500
Rapid-acting = rule of 1800

173
Q

Correction dose formula

A

(BG now - Target BG) / correction factor

174
Q

Converting between insulins: NPH to glargine

A

80% of NPH dose

175
Q

Converting between insulins: Toujeo to glargine or determir

A

80% of Toujeo dose

176
Q

Converting between insulins: Rapid to Short-acting insulin

A

1:1 ratio

177
Q

All insulin pens contain 3mL of insulin except Toujeo which is available in __ and ___

A

1.5mL and 3mL

178
Q

Room temp stability: Humalog mix 0/50 and 75/25 pens

A

10 days

179
Q

Room temp stability: Humulin 70/30 pen

A

10 days

180
Q

Room temp stability: Humulin N pen

A

14 days

181
Q

Room temp stability: Novolog Mix 70/30 pen

A

14 days

182
Q

Room temp stability: Apidra, Humalog, Novolog, Amdelog, Lyumjev, Fiasp pens and vials

A

28 daysM

183
Q

Room temp stability: Humalog Mix 75/25 vial

A

28 days

184
Q

Room temp stability: Novolog Mix 70/30 vial

A

28 days

185
Q

Room temp stability: Novolin R U-100, N and 70/30 pens

A

28 days

186
Q

Room temp stability: Humulin R U-500 pen

A

28 days

187
Q

Room temp stability: Lantus, Basaglar, Semglee vials and pens

A

28 days

188
Q

Room temp stability: Humulin R U-100, N, and 70/30 vials

A

31 days

189
Q

Room temp stability: Humulin R U-500 vial

A

40 days

190
Q

Room temp stability: Novolin R U-100, N, and 70/30 vials

A

42 days

191
Q

Room temp stability: Levemir vial and pen

A

42 days

192
Q

Room temp stability: Tresiba pen

A

56 days

193
Q

Room temp stability: Toujeo pen

A

56 days

194
Q

Use a ___ insulin syringe for < 30 units

A

0.3 mL

195
Q

Use a ___ insulin syringe for 30-50 units

A

0.5 mL

196
Q

Use a ___ insulin syringe for 51-100 units

A

1mL

197
Q

What color are U-500 syringes vs U-100 syringes caps?

A

U-500 are GREEN
U-100 are ORANGE

198
Q

Higher the gauge, (thicker/thinner) the needle

A

Thinner

199
Q

S/sx of hypoglycemia

A

Dizziness, anxiety/irritability, shakiness, HA, diaphoresis (sweating), hunger, confusion, nausea, ataxia, tremors, palpitations/tachycardia and blurred vision
(Severe = seizures, coma, and death)

200
Q

Beta-blockers, especially if ____, can cause hypoglycemia and mask adrenergic symptoms. ___ and __ are NOT masked.

A

Non-selective
Sweating and hunger are NOT masked

201
Q

Drug list that increase BG

A

Beta-blockers (+/-)
Thiazide and loop diuretics
Tacrolimus, cyclosporine
Protease Inhibitors
Quinolones (+/-)
Antipsychotics (e.g. olanzapine, quetiapine)
Statins
Steroids (systemic)
Cough syrups
Niacin

Others: Azole antifungals (systemic), beta-agonists, octreotide (+/-)

202
Q

Drug list that decrease BG

A

Beta-blockers (+/-)
Quinolones (+/-)
Tramadol

Others: linezolid, octreotide (+/-), pentamidine, quinine

203
Q

Inpatient target BG range

A

140-180

204
Q

DKA can be recognized by 3 things: ___, ___, and ___

A

BG > 250
Ketones (urine and serum, “fruity breath”), abdominal pain, N/V, dehydration
Anion gap (arterial pH <7.35, anion gap > 12)

205
Q

DKA is more common in Type __ DM while hyperosmolar hyperglycemic state (HSS) is more common in Type __ DM

A

DKA = T1DM
HHS = T2DM

206
Q

Pirmary cause of HHS is ___

A

illness that leads to less fluid intake

207
Q

HHS is recognized by 4 things: ___, ___, ___, and ___

A

Confusion ,delirium
BG > 600 with high serum osmolality > 320 mOsm/L
Extreme dehydration
pH > 7.3, bicarbonate > 15 mEq/L

208
Q

DKA and HHS treatment

A

Primary = fluids
Regular insulin infusion (0.1 units/kg bolus and then 0.1 units/kg/hr cont infusion OR 0.14 units/kg/hr continuous infusion)
Prevent hypokalemia - monitor K
Treat acidosis if pH <6.9 (sodium bicarb prn)

209
Q

Regular insulin infusion dosing (2 ways)

A
  1. 0.1 units/kg bolus, 0.1units/kg/hr continuous infusion
  2. 0.14 units/kg/hr continuous infusion (no bolus)
210
Q

Which DM meds should be avoided: cancer (thyroid, including medullary thyroid carcinoma)

A

GLP-1 agonists, GLP-1/GIP agonists

211
Q

Which DM meds should be avoided: Gastroparesis, GI disorders

A

GLP-1RA, GLP-1/CIP agonists, pramlintide

212
Q

Which DM meds should be avoided: Genital infection/UTI

A

SGLT2i

213
Q

Which DM meds should be avoided: HF

A

TZDs, alogliptin, saxagliptin

214
Q

Which DM meds should be avoided: hypoglycemia

A

insulin, SU, meglitinides, pramlintide

215
Q

Which DM meds should be avoided: hypotension/dehydration

A

SGLT2i

216
Q

Which DM meds should be avoided: hypokalemia

A

insulin

217
Q

Which DM meds should be avoided: Ketoacidosis

A

SGTL2i (can occur when BG <250); increased risk with acute illness, dehydration, renal impairment – d/c prior to surgery to reduce risk

218
Q

Which DM meds should be avoided: Lactic acidosis

A

Metformin; increased risk with renal impairment, alcoholism, hypoxia

219
Q

Which DM meds should be avoided: osteopenia/osteoporosis

A

Canagliflozin (Invokana) (decreased BMD, fractures), TZDs (fractures)

220
Q

Which DM meds should be avoided: Pancreatitis

A

DPP-4i, GLP1RA, GLP-1/GIP agonists

221
Q

Which DM meds should be avoided: Peripheral neuropathy, PAD, foot ulcers

A

canagliflozin (Invokana)

222
Q

Which DM meds should be avoided: Sulfa allergy, severe

A

SU consider avoiding or use cautiously

223
Q

Which DM meds should be avoided: renal insufficiency (eGFR or CrCl <30)

A

Metformin, exenatide, glyburide; may need to start insulin at lower dose

224
Q

Which DM meds should be avoided: weight gain/obesity

A

SU, meglitinides, TZDs, insulin

NAPLEX 2024 (74 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions